论文部分内容阅读
目的观察β受体阻滞剂联合ARB类治疗CHF的临床价值。方法将本院2011年3月至2012年7月收住CHF患者135例随机分为β受体阻滞剂组、ARB组及联合治疗组,三组患者均在给药前进行基础常规治疗。结果联合治疗组临床效果显著优于β受体阻滞剂组及ARB组(P<0.05),且联合用药组住院频率、心率等指标好于另两组。结论β受体阻滞剂联合ARB类药物治疗CHF患者能显著降低不良事件的发生率,提高患者生活质量,值得临床推广使用。
Objective To observe the clinical value of β-blocker combined with ARB in the treatment of CHF. Methods A total of 135 patients admitted to our hospital from March 2011 to July 2012 were randomly divided into β-blocker group, ARB group and combination therapy group. All three groups were given basic routine treatment before administration. Results The clinical effect of combined treatment group was significantly better than that of β-blocker and ARB group (P <0.05). The frequency of hospitalization and heart rate in combination group were better than the other two groups. Conclusion The combination of β-blocker and ARB can significantly reduce the incidence of adverse events and improve the quality of life of patients, which is worthy of clinical application.